EAM Global Investors’s Catalyst Pharmaceutical CPRX Stock Holding History

EAM Global Investors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-111,542	Closed	-$2.07M	–	114
2022 Q4	$2.07M	Sell	111,542 -47,748	-30%	-$735K	0.54%	64
2022 Q3	$2.04M	Sell	159,290 -86,686	-35%	-$1.03M	0.54%	66
2022 Q2	$1.72M	Sell	245,976 -46,789	-16%	-$343K	0.42%	107
2022 Q1	$2.43M	Sell	292,765 -55,134	-16%	-$390K	0.45%	77
2021 Q4	$2.35M	Buy	+347,899	New	+$2.29M	0.42%	124
2019 Q2	–	Sell	-276,228	Closed	-$1.41M	–	136
2019 Q1	$1.41M	Buy	+276,228	New	+$812K	0.62%	79
2018 Q1	–	Sell	-251,647	Closed	-$984K	–	148
2017 Q4	$984K	Buy	+251,647	New	+$831K	0.5%	92

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

EAM Global Investors's CPRX Position: Q1 2023 in Review

EAM Global Investors sold out of Catalyst Pharmaceutical (CPRX) in Q1 2023, closing a stake of 111,542 shares — an estimated $2.07M sold.

EAM Global Investors first reported a position in CPRX in Q4 2017 and held it in 7 quarters. The position peaked at $2.43M in Q1 2022. 259 funds tracked by Wall St. Rank hold CPRX as of Q1 2023.

EAM Global Investors reported no remaining Catalyst Pharmaceutical position as of Q1 2023 after selling out during the quarter.
EAM Global Investors sold 111,542 Catalyst Pharmaceutical shares in Q1 2023, an estimated $2.07M.
EAM Global Investors first reported a position in Catalyst Pharmaceutical in Q4 2017 and held it in 7 quarters.
EAM Global Investors's Catalyst Pharmaceutical position peaked at $2.43M in Q1 2022.
259 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2023.

Based on EAM Global Investors's 13F filing for Q1 2023, filed 15 May 2023.